SARS-CoV-2 antibody determination in a vaccinated and recovered cohort in Austria

Elisabeth Mara; Tobias Mader; Johannes Gratzer; Stefanie Hochegger; Thomas Pekar

doi:10.1016/j.clicom.2022.08.001

SARS-CoV-2 antibody determination in a vaccinated and recovered cohort in Austria

Clin Immunol Commun. 2022 Dec:2:136-141. doi: 10.1016/j.clicom.2022.08.001. Epub 2022 Sep 14.

Authors

Elisabeth Mara¹, Tobias Mader¹, Johannes Gratzer¹, Stefanie Hochegger¹, Thomas Pekar¹

Affiliation

¹ Biomedical Science, University of Applied Sciences Wiener Neustadt, Austria.

Abstract

Since December 2019 the world has been dealing with a severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) pandemic. The first SARS-CoV-2 vaccine was made available in Europe at the end of 2020. 202 volunteers from the vicinity of the University of Applied Sciences Wiener Neustadt took part in this study; their IgG levels recognizing the RBD of SARS-CoV-2 were determined. The aim was to evaluate the SARS-CoV-2 titer levels of vaccinated, recovered and vaccinated plus recovered persons. We could show that there is a significant difference in the antibody levels of vaccinated, vaccinated plus recovered and only recovered probands. Additionally, the highest antibody levels were found in triple vaccinated persons. Furthermore, the Moderna vaccine seems to have a higher immune response.

Keywords: IgG determination; RBD; SARS-CoV-2; Vaccine.